title: The aging process: where are the drug opportunities?
abstract: New data support a role for growth hormone secretagogue receptor agonists as rejuvenating agents. Two enzymes critical for the formation of beta-amyloid plaques in Alzheimer's disease have been identified. Estrogen receptor beta continues to emerge as a potential drug target. The orphan nuclear receptor Nurr1 appears to be a target for treatment of Parkinson's disease, and propargylamines are emerging as inhibitors of oxidative damage in neurons.
authors.affiliation: Huffington Center on Aging and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA. rsmith@bcm.tmc.edu
authors.forename: R G
authors.initials: RG
authors.lastname: Smith
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000187:drug effects*; D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism; D000682:Amyloid / Q000378:metabolism; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects; D004268:DNA-Binding Proteins; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D057126:Nuclear Receptor Subfamily 4, Group A, Member 2; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D011960:Receptors, Estrogen / Q000819:agonists; D013141:Spiro Compounds / Q000627:therapeutic use; D014157:Transcription Factors / Q000378:metabolism
chemical_list: D000682:Amyloid; D000978:Antiparkinson Agents; D004268:DNA-Binding Proteins; D007211:Indoles; D008996:Monoamine Oxidase Inhibitors; C539882:NR4A2 protein, human; C539884:Nr4a2 protein, rat; D057126:Nuclear Receptor Subfamily 4, Group A, Member 2; D011960:Receptors, Estrogen; D013141:Spiro Compounds; D014157:Transcription Factors; C094817:ibutamoren mesylate